Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Point of Care Tests to Help Reduce Overuse of Antibiotics

By LabMedica International staff writers
Posted on 27 Jan 2025

The misuse of antibiotics—such as taking them unnecessarily, for too long, or in incorrect doses—leads to antimicrobial resistance (AMR), making infections harder to treat and increasing the risks of severe illness and death. More...

AMR causes 700,000 global deaths annually, and many people either expect antibiotics from doctors or misuse them by not following prescribed dosages. Doctors face challenges in prescribing antibiotics due to diagnostic uncertainty, patient self-diagnosis, and limited resources. Now, two new tests for bacterial infections could help reduce the overuse of antibiotics for common respiratory illnesses.

Researchers at Deakin University (Victoria, Australia) are leading trials of the two new tests involving a simple finger prick or throat swab that provide immediate results to distinguish between bacterial and viral infections. This can enable more accurate diagnoses and targeted treatments, potentially reducing unnecessary antibiotic prescriptions. In international trials conducted earlier, the finger prick test has already shown promise, while early results from the latest trial indicate a reduction of antibiotic use by up to 30%. This test can help doctors determine if common respiratory infections are bacterial or viral, ensuring antibiotics are only prescribed when necessary.

The second test, a throat swab, allows doctors to quickly identify if a sore throat is caused by Strep A bacteria, a common source of throat infections. Despite Strep A being responsible for only 15 to 20% of sore throats, antibiotics are often overprescribed in 70% of cases. Proper diagnosis and early treatment are critical, especially in children, as Strep A can lead to severe complications like rheumatic heart disease. This throat swab test will optimize antibiotic treatment for Strep A. A feasibility trial conducted in 2024 with 200 patients across five clinics, followed by a pilot trial in 2025 with 400 patients, aims to further assess the test’s effectiveness in reducing antibiotic overuse. Both these trials hold the potential to significantly improve the responsible use of antibiotics.

“This work is trying to improve the capacity of GPs and community pharmacists with point-of-care diagnostic testing services,” said Dr. Sajal Saha, Research Fellow in the Centre for Innovation in Infectious Disease and Immunology Research. “This will help prescribers better understand the severity of infections or confirm bacterial infections for some respiratory infections during patient consultations and prescribe antibiotics accordingly.”

Related Links:
Deakin University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Dr. Maria “Ken” Figueroa is investigating how epigenetics can inform treatment paths for cancer patients. (Image Credit: Sylvester Comprehensive Cancer Center)

DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are disorders in which the bone marrow does not produce healthy blood cells normally. Treatment selection can be challenging because clinicians cannot reliably predict which... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: Melioidosis is a serious, sometimes fatal infection caused by Burkholderia pseudomallei, a bacterium found in tropical and subtropical soil and surface water. (Image Credit: Adobe Stock)

Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions

Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Siemens Healthineers has begun carving out its in vitro diagnostics business as a standalone company named Olyrian Diagnostics (Photo courtesy of Siemens Healthineers)

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.